StimRouter™ for Pain Management in Post-stroke Shoulder Pain

NCT ID: NCT03093935

Last Updated: 2021-01-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-01
• Study Completion Date: 2020-11-20

Brief Summary

StimRouter Neuromodulation System includes an implanted lead which provides peripheral nerve stimulation for chronic pain. Post-stroke shoulder pain patients will be the focus of this study. After meeting inclusion/exclusion criteria, approximately 50 enrolled patients will participate in the study through 6 months of follow-up. Various measures will be used to assess patient response to use of the device.

Detailed Description

Adults age 18 or over with severe intractable chronic shoulder pain subsequent to stroke will be included. Pain relief will be measured after using StimRouter stimulation therapy targeting the axillary nerve. Existing/pre-study pain medications must be either maintained, reduced throughout the trial.

Study Design is prospective, multi-center and will include 50 subjects The primary endpoint will be a clinically relevant pain reduction (30%) in pain score at 3 months after initiating stimulation in at least 50% of patients with no increase in pain medication.

Primary Outcomes: Reduction of average pain at rest measured by numeric scale (BPI-SF5)

Secondary Outcomes

1. Change in Worst Pain (BPI-SF3)

2. Least Pain & Pain Right Now (BPI - SF 4,6)

3. Patient Global Impression of Change (PGIC)

4. Patient Satisfaction questionnaire

5. Shoulder Q Data Collection Points

1) Baseline 2) Month 1 post-programming 3) Month 2 post-programming 4) Month 3 post-programming 5) Month 6 post-programming Data Analysis Analyses will be made to evaluate differences in outcomes compared to baseline measures, with primary endpoint at Month 3

• Standard statistical estimation and inference will be undertaken for the observed treatment effect.
• All adverse events will be tabulated by their frequencies and proportions.

Conditions

Chronic Pain; Hemiplegic Shoulder Pain

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

StimRouter Neuromodulation System

All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.

Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction).

Group Type: EXPERIMENTAL

StimRouter Neuromodulation System

Intervention Type: DEVICE

The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.

Interventions

StimRouter Neuromodulation System

The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.

Intervention Type: DEVICE

Other Intervention Names

StimRouter

Eligibility Criteria

Inclusion Criteria

• Male or female age ≥18 years and confirmed diagnosis of stroke
• Competent to provide consent and comply with study requirements
• Minimum 3 months of severe chronic focal post-stroke shoulder pain
• Stable regimen of pain medications for >4 weeks prior to implant and willing to maintain equivalent dosage throughout the study
• A mean score of > 4 on the Brief Pain Inventory short form, question 3 (BPI-SF3)
• Capable and willing to follow all study-related procedures
• Able to tolerate surface stimulation as demonstrated by motor level response at shoulder

Exclusion Criteria

• Patients who decline to provide written consent or to attend follow-up visits
• Shoulder pathology (e.g. rotator cuff tear, frozen shoulder etc) at target limb
• Evidence of a primary central or regional pain pattern inclusive of shoulder
• Diagnosed/confirmed shoulder dysfunction
• Botox or other neurolytic agent injections in last 3 months
• Any confounding neurologic conditions affecting the upper limb
• Evidence or history of skin infections
• History of adverse reactions to local anesthetics (e.g. lidocaine) or adhesives
• Patients who have an active systemic infection or are immunocompromised
• Patients who are pregnant, intend to become pregnant, are breastfeeding or of child-bearing potential and not practicing a medically-approved method of birth control
• Currently requiring or likely to require Magnetic Resonance Imaging (MRI) within the MRI exclusion zone defined as within 50cm of the iso-center or 16 cm of the MR coil as measured from the edge of the MRI coil.
• Any metallic implant in the immediate area intended for implant (e.g. TSR)
• Has demand-type cardiac pacemaker, defibrillator, or electrical nerve implant
• Potential need for diathermy at the implant site
• Potential need for therapeutic ultrasound at the implant site
• Patients who have already been implanted with StimRouter TM prior to study enrollment
• Presence of a documented condition or abnormality that could compromise the safety of the patient
• Life expectancy of less than 1 year

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bioness Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Keith McBride

Role: STUDY_CHAIR

Bioness Inc

Locations

University of Miami

Miami, Florida, United States

University of Utah

Salt Lake City, Utah, United States

Countries

United States

Other Identifiers

STMR Pain 002 PSSP

Identifier Type: -

Identifier Source: org_study_id